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Abstract: This study aims to review pediatric pulmonary hypertension (PH) by comparing the guidelines of the European Society of
Cardiology (ESC)/European Respiratory Society (ERS), the American Heart Association (AHA)/American Thoracic Society (ATS),
and the European Pediatric Pulmonary Vascular Disease Network (EPPVDN). All three sets of guidelines define PH as having a mean
pulmonary artery pressure of ≥25 mmHg and accept the validity of the World Health Organization (WHO) classification system. Every
child with a high index of suspicion for PH should undergo an initial work-up of chest X-rays, electrocardiography, and echocardiography.
The AHA/ATS guidelines emphasize the necessity of cardiac catheterization and hemodynamic studies. As mentioned in the AHA/ATS
guidelines, the symptoms and tests that can detect PH include right ventricle failure, WHO functional class, syncope, echocardiography
findings, hemodynamic data, brain natriuretic peptide (BNP)/N-terminal pro-BNP, the 6-min walk test, and cardiopulmonary exercise
tests. The EPPVDN guidelines refer to positive acute vasoreactivity test results and growth as risk factors. All three guidelines highlight
the importance of treating and following affected children in specialized centers and recommend calcium channel blockers as a first-line
treatment in children (aged >12 months) who have a positive acute vasoreactivity test. Children with PH have distinct clinical features.
In order to overcome the controversies related to the optimal management of pediatric PH, well-designed clinical studies should be
carried out on a large cohort of affected children.
Key words: Child, classification, guideline, pulmonary hypertension, risk, treatment

1. Introduction
Pulmonary hypertension (PH) has traditionally been
considered within the context of adult diseases. Because
of this, the study of pediatric disease has been limited and
complicated by many unanswered questions throughout
the long history of PH.
The literature consists of many randomized controlled
studies that have been conducted on adults with PH, but
pediatric patients have either been the participants of
small-scale studies or they have constituted an insignificant
component of the cohort of large-scale studies. Other
problems are the inadequacy of monitorization parameters
and the lack of clinical studies focusing on treatment
regimens. Moreover, the pediatric doses of drugs
prescribed for PH are unspecified, and they are usually
extrapolated from adult studies (1–4).
The Panama Pediatric Pulmonary Vascular Disease
Group was the first to consider the clinical differences
between affected children and adults and, therefore, to
assess pediatric PH in detail (5). The guidelines from this
group included recommendations about the etiological
and functional classification of pediatric PH.
* Correspondence: kula@gazi.edu.tr

Later, the guidelines of the European Society of
Cardiology (ESC)/European Respiratory Society (ERS)
underlined the necessity for specific schedules for the
diagnosis, follow-up, and treatment of affected children
(6). Similarly, the American Heart Association (AHA)
and the American Thoracic Society (ATS) published new
joint guidelines that can be considered the first companion
guides for pediatric PH (7). As these joint guidelines
were based on expert opinion, the European Pediatric
Pulmonary Vascular Disease Network (EPPVDN) created
a new set of guidelines that aim to better observe the
requirements of pediatric patients (8). This study aims to
review pediatric PH by comparing the ESC/ERS, AHA/
ATS, and EPPVDN guidelines.
2. Definition
The most widely accepted definition of PH is one based on
a mean pulmonary artery pressure (mPAP) of ≥25 mmHg.
However, the Pulmonary Vascular Research Institute
observed that the definition of pediatric PH should be
differentiated from that of adult PH because children and
adults have different physiological characteristics. Thus,
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the concept of pediatric pulmonary hypertensive vascular
disease (PPHVD) was developed (5).
According to the guidelines of the ESC/ERS,
precapillary PH is defined as the combination of mPAP
of ≥25 mmHg, end-expiratory pulmonary artery wedge
pressure (PAWP) of >15 mmHg, and pulmonary vascular
resistance (PVR) of >3 Wood units (WU). However, this
definition is invalid for newborns. Moreover, children with
some cardiac pathologies and single ventricle physiology
could develop pulmonary vascular disease in the absence
of the aforementioned criteria.
The AHA/ATS guidelines provide a more detailed
definition based on mPAP of >25 mmHg in infants over
the age of 3 months at sea level. The combination of
mPAP of >25 mmHg, PAWP of <15 mmHg, and PVR
index of >3 WU.m2 is required to describe pulmonary
arterial hypertension (PAH). It should be emphasized
that the WU.m2 unit has been previously used to define
pediatric PH. The necessity of using the WU.m2 unit in
the description of pediatric PH has been assessed recently
(9). Additionally, the AHA and ATS described pulmonary
hypertensive vascular disease as having a transpulmonary
gradient of >6 mmHg or a high PVR index in patients with
cavopulmonary anastomoses and normal mPAP values.
In May 2016, the EPPVDN revised its definition
of PH as having an mPAP of ≥25 mmHg and a PVR
index of >3 WU.m2 for biventricular circulation, a mean
transpulmonary gradient of >6 mmHg, or a PVR index of
>3 WU.m2 for cavopulmonary anastomosis (e.g., Fontan
physiology).
3. Classification
The ESC/ERS, AHA/ATS, and EPPVDN guidelines accept
the validity of the classification system for pediatric PH
put forward by the World Health Organization (WHO)
and most recently revised at the Fifth World Symposium
for Pulmonary Hypertension, held in Nice, France (Table)
(10). Both the AHA/ATS and EPPVDN guidelines stress
that more research is needed to approve the validity of the
Panama Classification System.
4. Diagnosis
All three guidelines agree with the recommendation
that children with PH should be followed and treated
in specialized centers as this disease has a complicated
pathophysiology. Generally, there is no marked difference
between the three guidelines with respect to diagnostic
tests and algorithms.
Each patient with a high index of suspicion for
PH should undergo an initial workup of chest X-rays,
electrocardiography, and echocardiography. The AHA/
ATS guidelines expressly emphasize the necessity of cardiac
catheterization and hemodynamic studies in clinical
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diagnosis and monitorization (Figure). The EPPVDN
guidelines further analyze cardiac-computed tomography
and magnetic resonance imaging (11), transthoracic
echocardiography, (12) and cardiac catheterization–
hemodynamic studies (13) under separate headings.
Different from the AHA/ATS guidelines, the EPPVDN
guidelines include different recommendation tables for
each of these diagnostic and monitorization methods.
The AHA/ATS guidelines accept the WHO system
for functional classification but also indicate that this
system has limited value in patients under 8 years of
age. On the other hand, the EPPVDN guidelines state
that the functional classification system proposed by the
Pulmonary Vascular Research Institute requires external
validation and correlation with clinical outcomes in
children (14).
In accordance with the sophisticated pathogenesis
of pediatric PH, both the AHA/ATS and EPPVDN
guidelines specifically address genetic defects, congenital
heart diseases, acute or chronic pulmonary diseases, and
intensive care as underlying causes. What is noteworthy
here is that the EPPVDN guidelines consider these
underlying causes as independent articles and offer
different recommendation tables for each one. That is, the
diagnostic and therapeutic algorithms for children with
congenital heart disease differ from those established for
children with parenchymal lung disease (15–18).
5. Risk evaluation
The ESC/ERS guidelines determine that children with
PH should be evaluated differently than adults. This
recommendation is based on the findings of Ivy et al.
(19) about pediatric PH. In contrast with the ESC/ERS
guidelines, the AHA/ATS guidelines do not delineate
an “intermediate risk” group. The risk factors identified
by the AHA/ATS guidelines consist of right ventricle
failure, WHO functional class, syncope, echocardiography
findings, hemodynamic data, brain natriuretic peptide
(BNP)/N-terminal pro-BNP, the 6-min walk test distance,
and cardiopulmonary exercise test results. In addition, the
AHA/ATS guidelines use the term “significant increase/
worsening” instead of referring to specific values for
echocardiographic findings and BNP/N-terminal proBNP concentrations.
The AHA/ATS guidelines can be distinguished from
the ESC/ERS guidelines in the way they feature the PVR
index and PVR/systemic vascular resistance (SVR) among
hemodynamic parameters. The EPPVDN guidelines also
cite PVR index of >15 WU.m2, mean right atrium pressure
(mRAP) of >15 mmHg, and the mPAP/mRAP ratio
(rather than the PVR/SVR ratio) as the hemodynamic
factors for high risk (mPAP/sPAP > 0.75). The major
disparity of the EPPVDN guidelines is the inclusion of an
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Table. Classification of pulmonary hypertension (PH).
1. Pulmonary arterial hypertension
1.1. Idiopathic
1.2. Heritable

1.2.1. BMPR2 mutation
1.2.2. Other mutations

1.3. Drugs and toxins induced

1.4. Associated with

1.4.1. Connective tissue diseases
1.4.2. HIV infection
1.4.3. Portal hypertension
1.4.4. Congenital heart diseases
1.4.5. Schistosomiasis

1’ Pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis
1” Persistent pulmonary hypertension of the newborn
2. Pulmonary hypertension due to left heart disease
2.1. Left ventricular systolic dysfunction
2.2. Left ventricular diastolic dysfunction
2.3. Valvular disease
2.4. Congenital/acquired left heart inflow/outflow tract obstruction & congenital cardiomyopathies
2.5. Other
3. Pulmonary hypertension caused by lung disease or hypoxemia
3.1. Chronic obstructive pulmonary disease
3.2. Interstitial lung disease
3.3. Other pulmonary diseases with mixed restrictive and obstructive pattern
3.4. Sleep disordered breathing
3.5. Alveolar hypoventilation syndromes
3.6. Long-term exposure to high altitudes
3.7. Developmental lung diseases
4. Chronic thromboembolic disease
4.1. Chronic thromboembolic pulmonary hypertension
4.2. Other pulmonary artery obstructions
5. Pulmonary hypertension with unclear or multifactorial mechanisms
5.1. Hematological disorders

5.1.1. Chronic hemolytic anemia
5.1.2. Myeloproliferative disorders
5.1.3. Splenectomy

5.2. Systemic disorders

5.2.1. Sarcoidosis
5.2.2. Pulmonary histiocytosis
5.2.3. Lymphangioleiomyomatosis

5.3. Metabolic disorders

5.3.1. Glycogen storage diseases
5.3.2. Gaucher disease
5.3.3. Thyroid disorders

5.4. Others

5.4.1. Tumor obstruction
5.4.2. Fibrosing mediastinitis
5.4.3. Chronic renal failure
5.4.4. Segmental pulmonary hypertension
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Figure. Generalized diagnostic algorithm for pediatric pulmonary hypertension (PH).
ECG: electrocardiogram; CXR: chest X-ray; CTEPH: chronic thromboembolic pulmonary hypertension;
PVOD: pulmonary veno-occlusive disease; PCH: pulmonary capillary hemangiomatosis; IPAH: idiopathic
pulmonary arterial hypertension; HPAH: hereditary pulmonary arterial hypertension.

acute vasoreactivity test as a factor for low risk. It can be
concluded that the PVR/SVR or mPAP/mRAP ratios have
more significance than that of a designated PVR index
or mRAP values. The reason is that utilization of such
ratios would narrow the margin of error because of the
limitations of the Fick principle.
Another point to be taken into account is the utilization
of the 6-min walk test in the AHA/ATS guidelines (lower
risk vs. higher risk: >500 m vs. <300 m). The 6-min walk
test is usually regarded as an independent factor for the
morbidity and mortality of children over the age of 7
(20). The values designated for the 6-min walk test vary
with respect to age and anthropometric measurements.
This is why it would be more appropriate to evaluate each
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pediatric patient individually by using 6-min walk test
percentiles (21). On the contrary, the EPPVDN guidelines
refer to growth as a risk factor. Because PH is a chronic
and progressive disease, it would be prudent to expect its
hazardous effects on growth and development. Therefore,
listing growth as a risk factor would be a rational approach.
6. Treatment
All three guidelines have similar recommendations for
the treatment of PH. The guidelines indicate calcium
channel blockers as the first-line treatment in children
(aged over 12 months) with a positive acute vasoreactivity
test. As for the management of children with a negative
acute vasoreactivity test, the EPPVDN guidelines differ
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from the AHA/ATS guidelines in two ways. First, the
EPPVDN guidelines mention that combination treatment
is preferred in the early management of low risk patients
in the WHO functional class II and III categories. Second,
the EPPVDN guidelines qualify the Potts shunt and atrial
septostomy as decompression procedures before lung
transplantation.
The AHA/ATS and EPPVDN guidelines have different
recommendations for the management of children who
have congenital heart disease-associated PH. Both sets
of guidelines recommend that children with a PVR index
of <6 WU.m2 and a PVR/SVR ratio of <0.3 can undergo
surgery after a thorough preoperative examination.
The AHA/ATS guidelines point out that an acute
vasoreactivity test should be performed in all children
with congenital heart diseases who have a PVR index of >6
WU.m2 and a PVR/SVR ratio of >0.3. The guidelines also
indicate that surgery can be undertaken in children with a
positive acute vasoreactivity test after careful assessment
(fenestration if needed) is made. In the event that the acute
vasoreactivity test has a negative result, these children
should be reassessed after initiation of specific treatment
for PH.
The EPPVDN guidelines categorize children with
congenital heart diseases who show a PVR index of >6
WU.m2 and a PVR/SVR ratio of >0.3 into two groups:
children with a PVR index range of 6–8 WU.m2 and a PVR/
SVR ratio of 0.3–0.5 (gray zone), and children with a PVR
index of >8 WU.m2 and a PVR/SVR ratio of >0.5. Since
the EPPVDN guidelines do not offer different therapeutic
options for these two groups, it is uncertain why such a
categorization is mentioned.

Both the AHA/ATS and EPPVDN guidelines define
the management of intensive care-associated PH as a
distinct clinical entity. Moreover, the EPPVDN guidelines
offer differential treatment algorithms for persistent PH in
newborns and bronchopulmonary dysplasia or neonatal
chronic lung disease-related PH (14).
7. General approach
The ESC/ERS, AHS/ATS, and EPPVDN guidelines have
undertaken similar measures for the vaccination, physical
training, transportation, and support of affected children.
8. Conclusion
In 2011, the Panama Pediatric Pulmonary Vascular
Disease Group was the first to specifically investigate issues
surrounding children with PH. Since then, there has been
pronounced progress in the field of pediatric PH in several
ways. First, it has been well established that children with
PH have distinct clinical features. Second, the ESC/ERS,
AHA/ATS, and EPPVDN guidelines focusing on pediatric
PH were published within a 1-year period. All three sets of
guidelines have highlighted the importance of performing
the management and follow-up of affected children in
specialized centers. Third, the recommendations of the
aforementioned guidelines are usually based on expert
opinions rather than valid scientific data. In order
to overcome controversies surrounding the optimal
management of pediatric pulmonary hypertension, welldesigned clinical studies should be carried out on a large
cohort of affected children.
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